|
January 1, 2012
By:
Mason Tenaglia
Mason Tenaglia offers empirical defense of coupons and copay offset programs.
|
|
December 1, 2011
By:
Ben Comer
It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
|
|
September 1, 2011
By:
William Looney
Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?
|
August 1, 2011
By:
Jennifer Ringler
Why does the match against medicines compliance always seem to end in an easy knockout?
|
June 1, 2011
Successful negotiations require a willingness to take risks and an ability to adapt
|
May 1, 2011
According to Eli Lilly, managing alliances requires more than good people skills
|
|
April 1, 2011
Pfizer's Sarah Krug describes what's necessary to bridge the gap between the patient revolution and healthcare provider in the 21st century
|
September 1, 2006
By:
Jill Wechsler
The PPP approach asks pharma to identify promising drugs and conduct pre-clinical tests, instead of paying for costly late-stage clinical trials.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
